Stock Events

Orphazyme A/S 

kr859.9
2
-kr30.1-3.38% Today

Statistics

Day High
925
Day Low
850
52W High
1,525
52W Low
407
Volume
45
Avg. Volume
30
Mkt Cap
32.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26SepExpected
Q2 2019
Q4 2019
Q2 2020
Q4 2020
Q2 2021
Q1 2022
Q2 2022
-5.28
-4.95
-4.61
-4.28
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORPHA.CO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap33.5B
Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap32.95B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.
Sarepta Therapeutics
SRPT
Mkt Cap14.38B
Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.
Ionis Pharmaceuticals
IONS
Mkt Cap7.01B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap16.14B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.
Bluebird bio
BLUE
Mkt Cap133.39M
bluebird bio focuses on gene therapies for genetic diseases and cancer, competing in the rare disease treatment space.
Novo Nordisk
NVO
Mkt Cap481.67B
Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.
Pfizer
PFE
Mkt Cap163.88B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Orphazyme A/S does not have significant operations. Previously, it was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is based in Herlev, Denmark.
Show more...
CEO
Mr. Jakob Færch Bendtsen
Employees
1
Country
DK
ISIN
DK0060910917
WKN
000A2H7EV

Listings